Dr Lal PathLabs Ltd. is a leading diagnostic laboratory and pathology services provider in India. It was established in 1949 by Dr S.K. Lal and is headquartered in New Delhi. The company operates a network of over 2000 collection centers and more than 200 laboratories and provides services in over 300 cities and towns across India.
The company offers a wide range of clinical laboratory tests and services, including biochemical tests, immunological tests, microbiology tests, hematology tests, histopathology tests, cytology tests, and molecular diagnostics tests. It also provides a variety of preventive health checkup packages.
Dr Lal PathLabs has a strong presence in the online space and offers services such as online booking and test results, online payment, and home sample collection. The company is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
Recently Dr Lal Path Labs shared its Q2Fy2024 results, and the growth looks impressive. In this post, we will discuss more about Dr LalPathLabs and its share price target for November and December 2023 to 2030 through 2025.
Dr. LalPathLabs Stock History
The stock of Dr Lal PathLabs began trading on the NSE on April 21, 2017, and on the BSE on May 1, 2017. The stock has experienced a steady upward trend since then, with a peak of Rs. 4100 (as of September 9, 2021). Over the past year, the stock has gained approximately 163%.
In November 2023, the company reported a Q2 FY2024 revenue of Rs. 601 crores, up 12.5% YOY.
The company’s strong financial performance and its leadership position in the diagnostic laboratory industry are likely to drive the stock price higher in the near future.
Goldman Sachs has downgraded Dr Lal PathLabs: Know More
On October 18, 2023, Goldman Sachs downgraded Dr. Lal PathLabs to ‘sell‘. The investment bank cited intense competition and slower asset integration as the reasons for this downgrade. They also revised the target price for the company to Rs 2,100 from Rs 2,504, suggesting a potential downside.
Analysts anticipate a structural volume decline from earlier growth estimates and have concerns about the company’s stretched business-to-consumer (B2C) valuations.
However, as of November 3rd, 2023, Dr Lal Path Labs is trading at Rs. 2603 per share.
You can buy shares of Dr Lal PathLabs on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). You can buy shares through a stockbroker or an online trading platform.
To buy shares of Dr Lal PathLabs through a stockbroker, you must open a Demat and trading account with the stockbroker. You will have to fill out an account opening form, provide KYC documents, and submit the form with the required fees. Once you have opened the account, you can place an order to buy the shares of Dr Lal PathLabs.
Some online platforms to buy Lal PathLabs Stock are Zerodha, Upstox, 5Paisa, HDFC Securities, Angel Broking, ICICI Direct, Kotak Securities, etc.
For a better understanding, let us see the price targets and predictions for Lal PathLabs Limited’s share price over the years.
|When||Maximum Price||Minimum Price|
As of 3rd November 2023, the stock price of Dr. Lal PathLabs is trading at ₹ 2,617 with a market cap of ₹ 21,843 Crore.
Looking ahead to the end of November 2023, the stock is expected to range between ₹2,765.59 (maximum) and ₹2,332.35 (minimum).
Investor outlook for December 2023 shows a potential upside, with a maximum expected price of ₹2,850.25 and a minimum of ₹2,409.32.
The company is trading with an attractive valuation with a PE ratio of 72.5.
|When||Maximum Price||Minimum Price|
The projected share price targets for Dr Lal PathLabs in 2024 demonstrate a mix of potential highs and lows throughout the year. In January, the stock is expected to range between ₹2,804.34 (maximum) and ₹2,351.60 (minimum), showing a significant price range. February sees a slight decrease with a range of a maximum of ₹2,759.53 and a minimum of ₹2,399.59.
As the year progresses, March reveals a further uptick, with a maximum price of ₹2,815.85 and a minimum of ₹2,448.56. The fluctuations continue into April, May, and June, with varying price targets within this period.
In the latter half of 2024, more pronounced upward trends appear, with November and December potentially seeing a maximum price of ₹3,017.20 and ₹3,092.63, respectively. This indicates a more optimistic outlook for the stock as the year concludes, with investors possibly anticipating positive developments or growth for the company.
|When||Maximum Price||Minimum Price|
In 2025, Dr Lal PathLabs is expected to continue its bullish growth, as per the projected share price targets.
The year kicks off with a strong start, as January forecasts a price range between ₹2,426.53 (minimum) and ₹3,154.49 (maximum), indicative of a bullish trend. February continues this positive trajectory with a maximum price of ₹3,235.37 and a minimum of ₹2,488.75.
As the months progress, March and April demonstrate further optimism, with maximum prices of ₹3,361.55 and ₹3,295.64, respectively. May and June continue to show a strong upward trend, reinforcing investor confidence in the company’s future performance.
The latter half of 2025 is marked by a consistent bullish sentiment, with November and December potentially reaching maximum prices of ₹3,678.39 and ₹3,770.35, respectively. These projections suggest that investors anticipate a favorable outlook for Dr Lal PathLabs, possibly due to expected growth, market conditions, or company-specific developments.
|Year||Maximum Price||Minimum Price|
The projected share price targets for Dr Lal PathLabs from 2026 to 2030 indicate a promising outlook for the company. Starting in 2026, the stock is estimated to range between ₹2,771.21 (minimum) and ₹3,958.87 (maximum). Over the subsequent years, the price targets continue to climb, with the maximum price reaching ₹6,862.04 in 2030, showcasing substantial growth potential.
These projections reflect an optimistic long-term trajectory, suggesting that investors foresee continued expansion and strength in the healthcare and diagnostics sector, making Dr. Lal PathLabs an appealing investment prospect. However, market conditions and industry dynamics will play a crucial role in realizing these forecasts.
Lal PathLabs Financial Condition: Last 5 years
|Dr. Lal Pathlabs
|Profit before Tax||301||310||394||475||344|
Dr Lal PathLabs Q2 FY2024 Results: Summary
Dr Lal PathLabs on 2nd November 2023 posted their Q2 results, and here are the highlights:
- Dr Lal PathLabs reported a 52.4% year-on-year increase in consolidated net profit, reaching Rs 109.3 crore for the July-September quarter.
- Compared to the same quarter last year’s profit of Rs 72.4 crore, this is a substantial rise. The net profit for the preceding June quarter was Rs 83.6 crore.
- Revenue for the quarter was Rs 601 crore, marking a 12.6% increase from the year-ago figure of Rs 533.8 crore. Excluding RTPCR, revenue saw a 14.4% growth.
- EBITDA stood at Rs 177.8 crore with a margin of 29.6%, showing improvement from Rs 143.8 crore and 26.9% margin in the previous year.
- CEO Bharath Uppiliappan mentioned plans to accelerate expansion in Tier3+ towns, following positive results from their ongoing program.
- Dr. Om Manchanda, Managing Director, highlighted the company’s strategic growth initiatives, including their focus on Tier 3 and 4 towns, specialty portfolios, and building the Suburban brand in key Western markets.
- In the first half of FY24, the company served 1.4 million patients and processed over 40 million samples.
- The company’s cash balance saw an 86% increase, reaching Rs 780 crore this quarter, compared to Q2 of FY23.
Will Lal PathLabs Stock price grow in 2023?
The stock price of Dr. Lal PathLabs in 2023 is subject to fluctuations, with projected price targets ranging from ₹2,332.35 to ₹2,850.25.
What is the market cap of Dr Lal PathLabs?
As of November 3rd, 2023, the market capitalization of Dr Lal PathLabs is ₹ 21,843 Cr.
What future is anticipated for Dr Lal PathLabs in 2024?
In 2024, Dr. Lal PathLabs is anticipated to experience fluctuations in its stock price, with the potential for both highs and lows throughout the year, including a maximum price target of ₹3,092.63 in December.
Can Dr. Lal PathLabs reach 10,000 INR?
It is possible that the stock price of Dr. Lal PathLabs could reach 10,000 INR in the year 2029 or 2030.
However, it is impossible to predict exactly when this may happen as the stock price depends on several factors such as the company’s financial performance, market conditions, and investor sentiment. Investing in Dr Lal PathLabs shares could be a good option to generate returns.
The share price target for Dr. Lal PathLabs in 2025 shows an optimistic outlook, with a maximum projected price ranging from ₹2,426.53 to ₹3,770.35 during the year.
The share price target for Dr. Lal PathLabs in 2030 indicates substantial growth potential, with the maximum price projected to be ₹6,862.04, suggesting a positive long-term trajectory.
Dr Lal Pathlabs price target by JM Financial
JM Financial has set a price target of Rs 2620 with a buy rating. (20th March, 2023)
BNP Paribas suggested buying the stocks of Dr Lal Pathlabs with a projected price of Rs 2875 (Sep 28, 2022).
Dr Lal Pathlabs price target by ICICI Securities
ICICI Securities recommended buying Dr Lal Pathlabs with a price target of Rs 2910.
Dr Lal Pathlabs price target by UBS
Brokerage firm UBS suggests buying with a price projection of Rs 2800.
Sales Growth: Dr. Lal Pathlabs has demonstrated consistent sales growth over the past 10 years, with a compounded growth rate of 16%. The growth rates for the last 5 years and 3 years were 14% and 15% respectively. However, in the most recent TTM (trailing twelve months) period, the sales growth rate was negative at -3%.
Profit Growth: The company has shown steady profit growth over the years, with a compounded growth rate of 16% over the past 10 years. However, the growth rates for the last 5 years and 3 years were 7% and 2% respectively. In the most recent TTM period, the profit growth rate experienced a significant decline of -31%.
Stock Price CAGR: The stock price of Dr. Lal Pathlabs has delivered positive returns over various time frames. The compound annual growth rate (CAGR) for the stock price over the last 5 years was 20%, while over the last 3 years it was 13%. In the most recent 1-year period, the stock price recorded a growth rate of 11%.
Return on Equity (ROE): Dr. Lal Pathlabs has maintained a healthy return on equity. The ROE over the past 10 years averaged 24%, indicating efficient utilization of shareholder’s equity. The ROE for the last 5 years and 3 years were 22% and 21% respectively. In the most recent year, the ROE decreased to 15%.
Dr Lal PathLabs Ltd is a leading diagnostic laboratory and pathology services provider in India. It has been performing well in the last few years and is expected to continue its strong performance in the future. Analysts expect the stock price of Dr Lal PathLabs to reach Rs. 3,092.63 by March 2024.
The company’s strong financial performance and its leadership position in the diagnostic laboratory industry are likely to drive the stock price higher in the near future. Investing in Dr Lal PathLabs shares could be a good option to generate returns.
The Price-to-Earning ratio and Price-to-Book ratio of Dr. Lal Pathlabs are 72.5 and 12.27 respectively whereas the 52-week high is 2,640.00 and the 52-week low is 1762.05. Adding to the same, the Earnings per Share of the company decreased to 36.13.
In the last 6 months, the Lal Path Lab share price has gone up by 34.54%.
After the tremendous rise during the Covid times, the share price needed correction. The share price was corrected by more than 50% from its ATH. However, after the correction, the share price seems to be on an uptrend since April. I think Lal Path Labs is close to its true value. One can start accumulating Lal Path Labs for a long-term hold.
Disclaimer: The analyst or the co-founder of this blog holds Dr. Lal Path Labs in his portfolio. This article on ‘Dr Lal Path Lab Share Price Target 2023 to 2030‘ is for educational purposes only and not to be taken as any investment advice. Please consult a SEBI-registered financial advisor before investing in LalPathLabs.
What did we learn?
- 2 Dr. LalPathLabs Stock History
- 3 Goldman Sachs has downgraded Dr Lal PathLabs: Know More
- 4 How to buy Lal PathLabs shares in India?
- 5 Lal PathLabs Share Price Target 2023-2030
- 6 Lal PathLabs Financial Condition: Last 5 years
- 7 Dr Lal PathLabs Q2 FY2024 Results: Summary
- 8 FAQs
- 8.1 Will Lal PathLabs Stock price grow in 2023?
- 8.2 What is the market cap of Dr Lal PathLabs?
- 8.3 What future is anticipated for Dr Lal PathLabs in 2024?
- 8.4 Can Dr. Lal PathLabs reach 10,000 INR?
- 8.5 What is Dr Lal Path Lab’s share price target for 2025?
- 8.6 What is Lal Path Lab’s share price target for 2030?
- 9 Dr. Lal PathLabs Share Price Target by Experts
- 10 Dr. LalPathLabs Share: Key Points
- 11 Conclusion